After launching the Biopôle Start-up Fund in May 2021, Biopôle SA is delighted to announce the selection of two promising start-ups: Testmate Health and Atinary Technologies. They join Novostia, Genknowme, Adaptyv Biosystems and Alithea Genomics.
Biopôle Start-up Fund: Testmate Health and Atinary Technologies are nominated
“The fund will help us in three ways: first, invest in new equipment that we will need for the next stage of product development; second, finance lab rental and office space for our growing team; and third, support the cost of external services” – said Siew-Veena Sahi, Co-Founder and CEO of Testmate Health
. The company develops a rapid at-home self-testing kits, supported by digital health, that provide immediate results with equivalent accuracy to current lab tests. Testmate Health enables prompt detection of the four common STDs (Chlamydia, gonorrhoea, trichomoniasis and mycoplasma genitalium) without having to visit a clinic or wait days for a result.
“I would like to thank Biopôle, its Scientific Advisory Board and its Board of Directors for selecting us and providing support in our mission to accelerate the transition to a sustainable future” – said Loïc Roch, Co-Founder and CTO at Atinary Technologies
. Atinary is a deeptech startup that integrates AI, machine learning, robotics and cloud computing with R&D to revolutionize optimization and discovery of breakthrough materials. Atinary SDLabs Platform enables the lab of the future, a closed-loop Materials Acceleration Platform or self-driving laboratory.
Biopôle SA has an annual budget of approximately CHF 500,000 dedicated to helping accelerate the innovation of start-ups established at Biopôle; they can be active in any area of the life sciences, be it biotech, medtech, pharma, digital health, nutrition — or any other related field.
Companies interested in applying for the Biopôle Start-up Fund can find all the information they need by clicking on the button below.
The next application deadline is 15th March, 2022.
Discover the fund